You are here :
Home
Healthcare Market Research Reports
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
 |
Antispasmodics in combination with analgesics Antispasmodics in combination with analgesics and its peer markets - Healthcare IT outsourcing, |
Upcoming |
|
|
Bile Therapy Bile Therapy and its peer markets - Chromatography, Liver... |
Upcoming |
|
|
Liver Therapy, Lipotropics Liver Therapy, Lipotropics and its peer markets - Clinical Trial Management Systems (CTMS), |
Upcoming |
|
|
Calcium supplement Calcium supplement and Sodium Reducing Agents, Potassium... |
Upcoming |
|
|
Antithrombotic enzymes Antithrombotic enzymes and its peer markets - Platelet aggregation inhibitors excl. heparin, |
Upcoming |
|
|
Hematological Enzymes Hematological Enzymes and its peer markets - Other hem products, |
Upcoming |
|
|
Peripheral vasodilator enzymes Peripheral vasodilator enzymes and its peer markets - E-Clinical Trial Solutions, |
Upcoming |
|
|
Agents for treatment of hemorrhoids and anal fissures for topical use Agents for treatment of hemorrhoids and anal fissures for topical use and its peer markets - Immunoassay, |
Upcoming |
|
|
Cytotoxic antibiotics and related substances Cytotoxic antibiotics and related substances and its peer markets - Proteomics, |
Upcoming |
|
|
TEG/Thrombelastrography TEG/Thrombelastrography and ROTEM/Rotational Thromboelastrometry and |
Upcoming |
|
|
ROTEM/Rotational Thromboelastrometry ROTEM/Rotational Thromboelastrometry and TEG/Thrombelastrography and |
Upcoming |
|
|
Sonoclot Sonoclot and TEG/Thrombelastrography and |
Upcoming |
|
|
Global Live Attenuated Vaccines (LAV) Market The Global Live Attenuated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $2515 million in 2013 and expected to be $3633 million by 2018 at a CAGR of 7.6%. Live Attenuated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Global Inactivated Vaccines Market The Global Inactivated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $1958 million in 2013 and expected to be $2974million by 2018 at a CAGR of 8.7%. Inactivated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Global Sub-unit Vaccines Market The Global Subunit Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $91 million in 2013 and expected to be $134 million by 2018 at a CAGR of 8.1%. Subunit Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Global Toxoid Vaccines Market The Global Toxoid Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $468.1 million in 2013 and expected to be $644.8 million by 2018 at a CAGR of 6.6%. Toxoid Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Global Conjugate Vaccines Market The global conjugate animal vaccine market is mainly driven by the growing prevalence of animal diseases and increasing incidences of zoonotic diseases in humans. It was valued at $201.1 million in 2013 and is expected to reach $305.2 million by 2018 at a CAGR of 8.7% during the forecast period. The report analyzes the market by six segments/products: aquaculture, companion animal vaccines, equine, livestock, porcine, and poultry. The prominent players in the market are Sanofi-Aventis, Merck, Pfizer, Inc., Bayer AG, and Virbac. |
Upcoming |
|
|
Global Recombinant Vaccines Market The Global Recombinant Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $368.9 million in 2013 and expected to be $550.8 million by 2018 at a CAGR of 8.3%. Recombinant Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Global Dna Vaccines Market The global DNA animal vaccine market is mainly driven by growing prevalence of animal diseases and increasing incidences of zoonotic diseases in humans. It was valued at $142.5 million in 2013 and is expected to reach $232.4 million by 2018, at a CAGR of 10.3% for the forecast period. The report analyzes the market by six segments/products: aquaculture, companion animal vaccines, equine, livestock, porcine, and poultry. The prominent players in the market are Sanofi-Aventis, Merck, Pfizer, Inc., Bayer AG, and Virbac. |
Upcoming |
|
|
Animal Vaccines Animal Vaccines and Bacterial vaccines, Viral vaccines, |
Upcoming |
Healthcare
